What patent protection did Novartis get for alpelisib around 2009?
Alpelisib (PIQRAY) is an anticancer drug developed by Novartis. The key issue for “Novartis patent 2009 synthesis” queries is usually the earliest patent filings that supported the compound and its therapeutic use, which then created later exclusivity and follow-on protection.
However, the specific “2009” patent number(s), jurisdictions, and what exactly they cover (compound vs. method of treatment vs. formulation) aren’t included in the information you provided. To answer precisely, I’d need at least one of the following: the patent number you mean, the country (US/EP/WO), or a link to the patent record you’re looking at.
When do alpelisib exclusivities typically expire?
Drug exclusivity timelines depend on which protection is being considered (patent term vs. regulatory data exclusivity vs. supplementary protection in Europe). Without the exact patent(s) and jurisdiction(s) tied to the “2009” reference, I can’t give a reliable expiration date.
If you point me to the specific patent family (or share the patent number), I can help translate it into a practical “when could generics/biosimilars arrive” view.
Is there a DrugPatentWatch.com entry for alpelisib?
DrugPatentWatch.com tracks drug patent and exclusivity information and is often used to connect specific patents to filing and expiration timelines. You can check for alpelisib here: DrugPatentWatch.com.
If you share the alpelisib page details (or the patent list shown there), I can synthesize what the 2009-related protection covers and how it affects exclusivity.
Can you clarify what you mean by “2009 synthesis”?
People use “synthesis” in a few different ways in patent searches:
- “synthesis” meaning the drug’s chemical synthesis/patent claims
- “synthesis” meaning a summary of the 2009 patent(s) and their scope
- “synthesis” meaning a timeline synthesis (filings → grants → exclusivity → expiry)
Tell me which one you want and, ideally, the jurisdiction or patent number tied to “2009,” and I’ll produce a targeted summary.
Sources